US NIH allocates additional funding to develop pyrimidinedione product as an anti-HIV drug

Published: 2011-09-22 06:56:00

Updated: 2011-09-22 06:56:00

The US based ImQuest Pharmaceuticals Inc., a strategic partner of Samjin Pharmaceutical Co., has rectntly received an additional funding of $2.3 million from the National Institute of Allergy and Infectious Disease (NIAID/NIH) to support the development of pyrimidinedione inhibitors as topical mi...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK